For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Human Coagulation Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A bio similar form of recombinant activated factor VII is also available, but does not play any considerable role in the market.
Scope of the Report:
In the last several years, global market of human coagulation factor VII developed Fluctuating ly, with an average growth rate of 0.03%. In 2016, global capacity of Human Coagulation Factor VII is nearly 2309 K MG.
North America is the largest consumption market of Human Coagulation Factor VII, with sales market share 45.13%. The second place is Europe, following North America with the sales market share of 22%.And the Europe production market share of Human Coagulation Factor VII is 100%.
Asia (EX. China) is another important market of Human Coagulation Factor VII, enjoying 9.66% sales market share. And in China, the market share is 2.38%.
The worldwide market for Human Coagulation Factor VII is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Human Coagulation Factor VII in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- NovoNordisk
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Type I
- Type II
Market Segment by Applications, can be divided into
- Hemophilia Treatment
- Surgery
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Coagulation Factor VII product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Human Coagulation Factor VII, with price, sales, revenue and global market share of Human Coagulation Factor VII in 2017 and 2018.
Chapter 3, the Human Coagulation Factor VII competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Coagulation Factor VII breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Human Coagulation Factor VII market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Human Coagulation Factor VII sales channel, distributors, customers, research findings and conclusion, appendix and data source.